Advancing visible light optical coherence tomography in glaucoma detection

推进可见光光学相干断层扫描在青光眼检测中的应用

• 批准号: 10567788
• 负责人: Ji Yi
• 金额: $ 53.99万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10567788
• 关键词: 3-Dimensional; Action Potentials; Address; Affect; Animals; Axon; Axonal Transport; Benchmarking; Blindness; Blood; Blood Vessels; Blood flow; Cell Respiration; Cells; Cessation of life; Chronic; Clinical; Clinical Research; Complex; Cross-Sectional Studies; Cytoskeleton; Data; Detection; Development; Devices; Disease; Early Diagnosis; Event; Eye; F-Actin; Functional disorder; Ganglion Cell Layer; Generations; Glaucoma; Goals; Human; Image; Individual; Inner Plexiform Layer; Light; Lighting; Measurement; Measures; Methods; Microtubules; Modeling; Nerve; Neurofibrils; Neurons; Noise; Optic Disk; Optical Coherence Tomography; Optics; Oxygen; Oxygen Consumption; Oxygen saturation measurement; Papillary; Pathologic; Performance; Prevention; Prospective Studies; Public Health; Quality of life; Reporting; Resolution; Retina; Retinal Ganglion Cells; Role; Scanning; Sensitivity and Specificity; Severities; Signal Transduction; Spectrum Analysis; Speed; Structure; Suspect Glaucomas; Synapses; System; Testing; Thick; Thinness; Time; Tissues; United States; Validation; Visible Radiation; Vision; Visual; Visual Fields; axon injury; clinical care; design; field study; functional loss; ganglion cell; high risk; imaging biomarker; imaging modality; improved; macula; neuroprotection; novel; novel therapeutics; optical disc; preservation; prevent; programs; rate of change; retina circulation; retinal nerve fiber layer; submicron; success; therapy development; transmission process

PROJECT SUMMARY Glaucoma is a chronic, progressive, incurable disease that affects over 2 million individuals in the United States alone and over 60 million worldwide. Sensitive detection of early glaucoma damage is not only essential for vision preservation, but also can facilitate new neuroprotective therapy developments. In this proposal, we focus on two novel imaging markers enabled by visible light optical coherence tomography (VIS-OCT), namely the reflectance spectral marker from retinal nerve fiber layer (RNFL) and macular oxygen consumption. We showed in our recent cross-sectional clinical study that peripapillary RNFL reflectance spectral marker and arteriovenous oxygen saturation difference in the macular region better separated early stage of glaucoma suspect/pre- perimetric glaucoma eyes from normal ones than circumpapillary RNFL and macular ganglion cell complex (GCC) thickness. These promising results lead to three specific goals in the project. First, we will develop a second- generation dual channel VIS-OCT device to improve the resolution, total imaging range, and image quality to achieve near shot-noise limit performance. Second, we propose to characterize the macular oxygen consumption by combining blood oxygen saturation and flow and correlated with glaucoma severity. Macular region contains >30% of total RGCs in retina and is involved in early events in glaucoma. The macular visual damage impacts the quality of life the most since it is at the center of our vision. For the first time, we will provide quantitative assessment of macular oxygen consumption in a spectrum of glaucoma severity and shed light in the pathological role of vascular function in the early-stage glaucoma. Finally, we propose a prospective study to correlate VIS-OCT imaging markers, including RNFL reflectance spectral markers and macular oxygen markers, with the glaucoma worsening. We will evaluate whether VIS-OCT markers can detect the early damages proceeding to vision functional loss at a later point. IMPACT ON PUBLIC HEALTH: The successful completion of this program will rigorously evaluate the clinical performances of new VIS-OCT markers for early glaucoma detection, which is highly impactful in clinical care and blindness prevention.

项目概要 青光眼是一种慢性、进行性、无法治愈的疾病，在美国影响着超过 200 万人 仅此一项，全球就有超过 6000 万。早期青光眼损伤的灵敏检测不仅对于 保护视力，还可以促进新的神经保护疗法的发展。在这个提案中，我们重点关注 可见光光学相干断层扫描（VIS-OCT）实现的两种新型成像标记，即 视网膜神经纤维层 (RNFL) 的反射光谱标记和黄斑耗氧量。我们展示了 在我们最近的横断面临床研究中，乳头周围 RNFL 反射光谱标记和动静脉 黄斑区氧饱和度差异更好地分离青光眼疑似/预兆早期阶段 周边青光眼与正常眼相比，周围视乳头 RNFL 和黄斑神经节细胞复合体 (GCC) 厚度。这些有希望的结果导致了该项目的三个具体目标。首先，我们将开发第二个—— 新一代双通道 VIS-OCT 设备，提高分辨率、总成像范围和图像质量 实现接近散粒噪声极限的性能。其次，我们建议表征黄斑氧 通过结合血氧饱和度和流量来消耗消耗，并与青光眼严重程度相关。黄斑部 该区域包含视网膜 RGC 总量的 30% 以上，并且参与青光眼的早期事件。黄斑视觉 损害对生活质量影响最大，因为它是我们愿景的中心。我们将首次提供 对青光眼严重程度范围内的黄斑耗氧量进行定量评估，并为青光眼的治疗提供启示 血管功能在早期青光眼中的病理作用。最后，我们提出一项前瞻性研究 关联 VIS-OCT 成像标记，包括 RNFL 反射光谱标记和黄斑氧 标记物，青光眼恶化。我们将评估 VIS-OCT 标记是否可以检测早期 损害随后会导致视力功能丧失。对公众健康的影响：成功的 该计划的完成将严格评估新 VIS-OCT 标记物的临床表现，以用于早期治疗 青光眼检测，对临床护理和失明预防具有非常重要的影响。